ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $39.30 million. The enterprise value is $51.02 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 8.91 million shares outstanding. The number of shares has increased by 1.57% in one year.
| Current Share Class | 8.91M |
| Shares Outstanding | 8.91M |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | +4.54% |
| Owned by Insiders (%) | 29.38% |
| Owned by Institutions (%) | 12.97% |
| Float | 5.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.46 |
| Forward PS | n/a |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.59.
| Current Ratio | 3.11 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 35.70 |
| Debt / FCF | n/a |
| Interest Coverage | -4.68 |
Financial Efficiency
Return on equity (ROE) is -14.54% and return on invested capital (ROIC) is -4.04%.
| Return on Equity (ROE) | -14.54% |
| Return on Assets (ROA) | -3.85% |
| Return on Capital (ROIC) | -4.04% |
| Revenue Per Employee | $301,747 |
| Profits Per Employee | -$48,241 |
| Employee Count | 79 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, ImmuCell has paid $5,368 in taxes.
| Income Tax | 5,368 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.34% in the last 52 weeks. The beta is 0.60, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -4.34% |
| 50-Day Moving Average | 3.93 |
| 200-Day Moving Average | 4.28 |
| Relative Strength Index (RSI) | 51.68 |
| Average Volume (20 Days) | 23,673 |
Short Selling Information
The latest short interest is 15,472, so 0.17% of the outstanding shares have been sold short.
| Short Interest | 15,472 |
| Short Previous Month | 23,566 |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, ImmuCell had revenue of $23.84 million and -$3.81 million in losses. Loss per share was -$0.49.
| Revenue | 23.84M |
| Gross Profit | 6.89M |
| Operating Income | -2.74M |
| Pretax Income | -3.89M |
| Net Income | -3.81M |
| EBITDA | -49,834 |
| EBIT | -2.74M |
| Loss Per Share | -$0.49 |
Full Income StatementBalance Sheet
The company has $3.81 million in cash and $15.53 million in debt, giving a net cash position of -$11.72 million or -$1.32 per share.
| Cash & Cash Equivalents | 3.81M |
| Total Debt | 15.53M |
| Net Cash | -11.72M |
| Net Cash Per Share | -$1.32 |
| Equity (Book Value) | 26.41M |
| Book Value Per Share | 2.99 |
| Working Capital | 9.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$362,117 and capital expenditures -$350,853, giving a free cash flow of -$712,970.
| Operating Cash Flow | -362,117 |
| Capital Expenditures | -350,853 |
| Free Cash Flow | -712,970 |
| FCF Per Share | -$0.08 |
Full Cash Flow StatementMargins
Gross margin is 28.92%, with operating and profit margins of -11.49% and -15.99%.
| Gross Margin | 28.92% |
| Operating Margin | -11.49% |
| Pretax Margin | -15.96% |
| Profit Margin | -15.99% |
| EBITDA Margin | -0.21% |
| EBIT Margin | -11.49% |
| FCF Margin | n/a |